home · filing · 0001628908-25-000010
8-K filed February 4, 2025, 6:59 PM ET
ticker EVH
CIK 0001628908
leadership
confidence high
sentiment positive
materiality 0.75
Evolent Health enters cooperation with Engaged Capital, appoints Springstubb to board
Evolent Health, Inc.
Appointed Brendan Springstubb (Engaged Capital affiliate) to Board; he joins Strategy Committee.
Engaged Capital bound by standstill: cannot exceed 9.9% ownership or launch proxy contests.
M. Bridget Duffy resigned from Board effective Feb 3, 2025, not due to any disagreement.
Richard Jelinek to be named Chair of the Board at 2025 Annual Meeting, succeeding Cheryl Scott.
Board continues independent director search; five new independent directors added in three years.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Departed
M. Bridget Duffy
Director
EVH ·
Evolent Health, Inc.
Effective 2025-02-03
Filed February 4, 2025, 6:59 PM ET
On February 3, 2025, M. Bridget Duffy, MD resigned from the Board.
Appointed
Brendan Springstubb
Director
EVH ·
Evolent Health, Inc.
Effective 2025-02-04
Filed February 4, 2025, 6:59 PM ET
On February 4, 2025, the Board (1) appointed Mr. Springstubb as a director
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
M. Bridget Duffy resigned as Director at Evolent Health, Inc..
Action resigned
Role Director
Exact text from the filing
On February 3, 2025, M. Bridget Duffy, MD resigned from the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Brendan Springstubb was appointed as Director at Evolent Health, Inc..
Action appointed
Role Director
Exact text from the filing
On February 4, 2025, the Board (1) appointed Mr. Springstubb as a director
View on SEC.gov
Source: SEC EDGAR
accession 0001628908-25-000010
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.